The move—one that meet’s industry standards—confirms the Cryoport company’s commitment to providing quality and safety in the cold chain solutions space.
The 13,400 square-foot Belgium site will expand the company’s branded standardized bioprocessing, cryopreservation, and distribution solution for the cell therapy market, with a focus on leukapheresis starting materials.